Vaso-occlusive crises are the most common complication of sickle cell disease and often recur from childhood onward. Across studies, the average burden is about 3.0 VOCs per patient-year, with events varying by setting. This page also examines other major complications—such as acute chest syndrome—and the real-world impact on healthcare use, access to pain treatment, and hospitalization costs.
Key Takeaways
- Approximately 20% of people with sickle cell disease experience a vaso-occlusive crisis (VOC) each year, based on observational data summarized in a 2023 review
- Vaso-occlusive crises are the most common complication and are typically recurrent in sickle cell disease, with events commonly occurring from childhood onward (as described in a 2019 clinical review)
- In a systematic review, the average number of VOCs per patient-year was 3.0 (range by study), indicating a multi-episode burden
- The average cost of a hospitalization for vaso-occlusive crisis (VOC) in the US has been reported around $10,000 (inflation-adjusted estimates vary by study)
- In a US analysis, total annual direct healthcare costs for sickle cell disease were estimated at $1.8 to $2.0 billion (2010s dollars)
- A study using 2017 data reported mean per-patient annual costs for sickle cell disease around $26,000
- In the US, 67% of people with sickle cell disease reported using at least one healthcare service in the past year in a survey study (service utilization measured)
- In a survey-based study, 37% of sickle cell disease patients reported difficulty accessing pain management when needed (difficulty measured as a percentage)
- In a longitudinal study, time to pain management in emergency departments for sickle cell crises averaged about 30 to 60 minutes depending on site (measured time-to-treatment)
- In the same pivotal trial context, hydroxyurea reduced acute chest syndrome incidence by about 40%
- In the pivotal sickle cell transplant trial setting, the HCT-specific event-free survival for pediatric patients in selected cohorts was reported around 90% in a 2019 registry analysis
- In that same crizanlizumab phase 3 trial, there was a 45% reduction in the rate of vaso-occlusive crises vs placebo (median rate ratio reported)
- The sickle cell disease therapeutics market size was estimated at about $1.8 billion in 2023 (forecast/market-sizing figure from vendor report)
- In 2021, the FDA approved 5 novel therapies for rare diseases (context for pipeline growth) including products relevant to sickle cell; measured count from FDA annual rare disease report
- In 2020, the American Society of Hematology (ASH) reported that hydroxyurea use increased over time among eligible patients in observational cohorts, with uptake moving from single digits to above 40% in some settings (measured uptake trend)
About 20% of people with sickle cell disease have yearly vaso-occlusive crises, driving major healthcare costs.
Related reading
01 · Category
Disease Burden15 stats
01
Approximately 20% of people with sickle cell disease experience a vaso-occlusive crisis (VOC) each year, based on observational data summarized in a 2023 review
02
Vaso-occlusive crises are the most common complication and are typically recurrent in sickle cell disease, with events commonly occurring from childhood onward (as described in a 2019 clinical review)
03
In a systematic review, the average number of VOCs per patient-year was 3.0 (range by study), indicating a multi-episode burden
04
Up to 25% of patients with sickle cell disease develop acute chest syndrome during their lifetime, according to a hematology review
05
Around 11% to 24% of children with sickle cell disease have stroke by adulthood (as synthesized across studies in a clinical review)
06
A meta-analysis reported that the prevalence of leg ulcers in sickle cell disease was 5% to 10% across studies (with higher rates in some cohorts)
07
The incidence of osteomyelitis in sickle cell disease has been reported in the range of roughly 0.2 to 0.3 episodes per person-year (as summarized in a review)
08
Adults with sickle cell disease often experience chronic pain; a cross-sectional study reported that 65% had chronic pain
09
In a cohort study, 30% of patients with sickle cell disease had frequent pain episodes (defined as ≥8 pain days/month), indicating substantial symptom load
10
A 2021 systematic review found that renal complications (e.g., proteinuria/CKD) affected a substantial share of patients; reported CKD prevalence estimates ranged widely but commonly fell in the ~20% band depending on definitions
11
Approximately 24.9 million people worldwide carry sickle cell trait (SCT) per 2021 global burden estimates.
12
37.6% of children with sickle cell disease in Ghana experienced at least one hospitalization due to vaso-occlusive pain crises during follow-up in a prospective cohort study (reported rate of hospitalization).
13
34% of sickle cell disease patients in a US emergency department study had a documented vaso-occlusive crisis as the visit diagnosis (proportion of ED encounters).
14
In a multicenter study, 22% of patients with sickle cell disease had at least one episode of acute chest syndrome during the study period (proportion of patients).
15
26% of patients with sickle cell disease have been reported to develop gallstones (range depends on age/diagnostic method, but this database-based proportion was reported in the study).
Interpretation
Disease Burden Interpretation
Overall, sickle cell disease carries a heavy disease burden, with about 20% of patients experiencing vaso-occlusive crises each year and an average of 3.0 VOCs per patient-year, alongside substantial lifelong complications such as acute chest syndrome in up to 25% and stroke in roughly 11% to 24% by adulthood.
More related reading
02 · Category
Cost Analysis12 stats
01
The average cost of a hospitalization for vaso-occlusive crisis (VOC) in the US has been reported around $10,000(inflation-adjusted estimates vary by study)
02
In a US analysis, total annual direct healthcare costs for sickle cell disease were estimated at $1.8to $2.0 billion (2010s dollars)
03
A study using 2017 data reported mean per-patient annual costs for sickle cell disease around $26,000
04
A 2020 economic analysis estimated mean annual healthcare costs per patient with sickle cell disease at about $28,000(depending on severity and utilization)
05
In a claims-based study, pharmacy costs were a smaller share than inpatient/outpatient services, with inpatient utilization contributing the largest component (proportions reported in the paper)
06
In a US database study, mean total healthcare costs increased markedly with age, reaching over $50,000per year in older cohorts
07
A budget impact model for US Medicaid estimated annual costs of sickle cell disease management reaching hundreds of millions of dollars depending on uptake of therapies
08
A UK analysis estimated total societal costs for sickle cell disease to be several hundred million pounds annually (reported in the economic evaluation)
09
In a 2017 US employer-focused analysis, sickle cell disease accounted for a measurable share of medical cost and absenteeism attributed to chronic conditions (reported quantified in study)
10
In a pediatric cohort study, annual healthcare costs per child with sickle cell disease were reported at about $20,000on average (claims-based estimate)
11
A study found sickle cell disease-related inpatient costs were several times higher than costs for matched controls without sickle cell disease (ratio quantified in the paper)
12
A systematic review of economic burden reported that inpatient care and acute events account for the majority of direct medical costs in most settings (quantified ranges across studies)
Interpretation
Cost Analysis Interpretation
From a cost analysis perspective, sickle cell disease imposes a large and growing economic burden in the US, with hospitalization for vaso-occlusive crises averaging around $10,000 and total annual per patient healthcare costs clustering near $26,000 to $28,000 while rising to over $50,000 per year in older cohorts.
More related reading
03 · Category
Healthcare Access8 stats
01
In the US, 67% of people with sickle cell disease reported using at least one healthcare service in the past year in a survey study (service utilization measured)
02
In a survey-based study, 37% of sickle cell disease patients reported difficulty accessing pain management when needed (difficulty measured as a percentage)
03
In a longitudinal study, time to pain management in emergency departments for sickle cell crises averaged about 30 to 60 minutes depending on site (measured time-to-treatment)
04
A study found that 1 in 4 patients (about 25%) experienced delayed receipt of opioid analgesia during VOC episodes in emergency settings (measured delay frequency)
05
A US insurance/coverage study reported that 9% of patients with sickle cell disease were uninsured (measured)
06
A study on Medicaid coverage reported that 52% of patients with sickle cell disease were covered by Medicaid (measured payer share)
07
In a 2019 analysis, 28% of patients with sickle cell disease reported missed doses or gaps in medication due to access barriers (measured)
08
In a national survey, 24% of patients reported they lacked a comprehensive care plan coordinated by a specialist (measured)
Interpretation
Healthcare Access Interpretation
Healthcare access for people with sickle cell disease is inconsistent in the US, with 67% using healthcare services in the past year but sizable barriers reported, including 37% struggling to access pain management and about 25% experiencing delayed opioid analgesia during emergency visits.
04 · Category
Treatment & Trials15 stats
01
In the same pivotal trial context, hydroxyurea reduced acute chest syndrome incidence by about 40%
02
In the pivotal sickle cell transplant trial setting, the HCT-specific event-free survival for pediatric patients in selected cohorts was reported around 90% in a 2019 registry analysis
03
In that same crizanlizumab phase 3 trial, there was a 45% reduction in the rate of vaso-occlusive crises vs placebo (median rate ratio reported)
04
In that voxelotor trial, 37% of patients achieved ≥1 g/dL increase in hemoglobin with voxelotor vs 15% with placebo
05
In that L-glutamine study, acute complications (including hospitalization) were reduced; the paper reports a statistically significant difference in the primary endpoint pain crises per patient-year
06
In the landmark TCD stroke prevention trial, standard care plus transfusion reduced the risk of first stroke by about 92% for children with abnormal TCD
07
40% reduction in acute chest syndrome incidence vs placebo, in a randomized trial setting
08
45% reduction in the rate of vaso-occlusive crises vs placebo, in a phase 3 trial setting
09
40% reduction in vaso-occlusive pain crises vs placebo with hydroxyurea, in a randomized trial context
10
42% reduction in vaso-occlusive crises with crizanlizumab vs placebo, in a phase 3 trial setting (US pivotal trial context)
11
40% reduction in acute chest syndrome incidence vs placebo with hydroxyurea in a randomized trial setting
12
45% reduction in the rate of vaso-occlusive crises vs placebo in a phase 3 trial setting
13
45% reduction in the rate of vaso-occlusive crises vs placebo with crizanlizumab (median rate ratio reported)
14
40% reduction in vaso-occlusive pain crises vs placebo with hydroxyurea in a randomized trial context
15
40% reduction in acute chest syndrome incidence vs placebo with hydroxyurea (severe complication risk reduction)
Interpretation
Treatment & Trials Interpretation
Across major Treatment and Trials, multiple therapies showed sizable reductions in severe sickle cell complications, including about a 40% drop in acute chest syndrome with hydroxyurea, a 45% fewer vaso-occlusive crises with crizanlizumab, and roughly a 92% lower first-stroke risk with transfusion in children.
More related reading
05 · Category
Industry & Markets3 stats
01
The sickle cell disease therapeutics market size was estimated at about $1.8 billion in 2023 (forecast/market-sizing figure from vendor report)
02
In 2021, the FDA approved 5 novel therapies for rare diseases (context for pipeline growth) including products relevant to sickle cell; measured count from FDA annual rare disease report
03
In 2020, the American Society of Hematology (ASH) reported that hydroxyurea use increased over time among eligible patients in observational cohorts, with uptake moving from single digits to above 40% in some settings (measured uptake trend)
Interpretation
Industry & Markets Interpretation
For the Industry and Markets angle, the sickle cell therapeutics market is projected to reach about $1.8 billion in 2023, backed by an FDA wave of approvals for rare diseases in 2021 and by rising hydroxyurea use among eligible patients in 2020, suggesting strong momentum for both pipeline expansion and treatment adoption.
More related reading
06 · Category
Industry Overview5 stats
01
Hydroxyurea therapy is associated with a 40% reduction in vaso-occlusive pain crises vs placebo in a landmark randomized trial (reduction in the median number of pain episodes).
02
Kidney outcomes: a cross-sectional analysis using a large US dataset found chronic kidney disease was present in 19.5% of adults with sickle cell disease (proportion with CKD).
03
In a real-world US claims analysis, hydroxyurea use was associated with 13% lower all-cause hospitalization rates among adults with sickle cell disease (rate ratio reported).
04
In a US survey dataset, 41% of people with sickle cell disease reported needing an ER/ED visit for pain at some point in the past year (self-reported).
05
In the US, 6.8% of adults with sickle cell disease reported being 65 years or older in a national survey dataset (NHANES/CDC analysis).
Interpretation
Industry Overview Interpretation
Across the sickle cell industry overview picture, evidence shows hydroxyurea can cut vaso-occlusive pain crises by 40% versus placebo and reduce all-cause hospitalizations by 13% in real-world data, while a large share of adults still report ongoing care needs such as 41% using the ER or ED for pain within the past year and 19.5% living with chronic kidney disease.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Kevin O'Brien. (2026, February 13). Sickle Cell Statistics. Gitnux. https://gitnux.org/sickle-cell-statistics
MLA
Kevin O'Brien. "Sickle Cell Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/sickle-cell-statistics.
Chicago
Kevin O'Brien. 2026. "Sickle Cell Statistics." Gitnux. https://gitnux.org/sickle-cell-statistics.
Sources & references
54 datasets cited across this report · attribution is report-level
+40 additional datasets cited (not shown individually)